Idiopathic pulmonary fibrosis: Gender-age-physiology index stage for predicting future lung function decline

Chest

Volumn 149, Issue 2, 2016, Pages 491-498

  Salisbury, Margaret L ^a   Xia, Meng ^b   Zhou, Yueren ^b   Murray, Susan ^b   Tayob, Nabihah ^c   Brown, Kevin K ^d   Wells, Athol U ^e   Schmidt, Shelley L ^f   Martinez, Fernando J ^g   Flaherty, Kevin R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d DEPARTMENT OF MEDICINE   (United States)

^e ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^f SPECTRUM HEALTH   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Idiopathic pulmonary fibrosis; Interstitial lung disease; Lung function

Indexed keywords

CARBON MONOXIDE;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EVENT FREE SURVIVAL; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; FUNCTIONAL ASSESSMENT; GENDER AGE PHYSIOLOGY INDEX; HUMAN; LUNG DIFFUSION CAPACITY; LUNG INSUFFICIENCY; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TERTIARY CARE CENTER; CLINICAL TRIAL; COMPLICATION; DISEASE COURSE; EPIDEMIOLOGY; FOLLOW UP; FORCED EXPIRATORY VOLUME; LUNG FUNCTION TEST; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; RESPIRATORY INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; TRENDS; UNITED STATES;

DISEASE PROGRESSION; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; IDIOPATHIC PULMONARY FIBROSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESPIRATORY FUNCTION TESTS; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 84958040637     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.15-0530     Document Type: Article

References (29)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidencebased guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
2. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636-643.
3. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4): 431-440.
4. Collard HR, King TE Jr., Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168(5):538-542.
5. Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and sixminute-walk test. Am J Respir Crit Care Med. 2006;174(7):803-809.
6. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168(5):543-548.
7. Hanson D, Winterbauer RH, Kirtland SH, Wu R. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest. 1995;108(2):305-310.
8. Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171(6):639-644.
9. King TE Jr., Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001;164(7): 1171-1181.
10. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med. 2003;168(5): 531-537.
11. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(4):459-466.
12. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167(7):962-969.
13. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10): 684-691.
14. Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebocontrolled trial results. Am J Respir Crit Care Med. 2010;181(6):604-610.
15. Demedts M, Behr J, Buhl R, et al. Highdose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353(21):2229-2242.
16. King TE Jr., Behr J, Brown KK, et al. BUILD-1: a randomized placebocontrolled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177(1):75-81.
17. King TE Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-2092.
18. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779): 1760-1769.
19. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350(2):125-133.
20. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med. 2008;178(9):948-955.
21. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646-664.
22. Crapo RO, Morris AH. Standardized single breath normal values for carbon monoxide diffusing capacity. Am Rev Respir Dis. 1981;123(2):185-189.
23. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1): 179-187.
24. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26(4): 720-735.
25. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.
26. Schmidt SL, Tayob N, Han MK, et al. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest. 2014;145(3):579-585.
27. Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax. 2012;67(5):407-411.
28. Ley B, Bradford WZ, Weycker D, Vittinghoff E, du Bois RM, Collard HR. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1374-1381.
29. Strand MJ, Sprunger D, Cosgrove GP, et al. Pulmonary function and survival in idiopathic vs secondary usual interstitial pneumonia. Chest. 2014;146(3): 775-785.